Agilus Diagnostics has announced a ground-breaking achievement in genomic testing with its industry-leading 3-day turnaround time (TAT) for test results in myeloid malignancies.

The genomic testing market in India is experiencing rapid growth, driven by advancements in technology, increasing awareness, and the rising demand for personalized medicine. Currently valued at approximately $150 million, the market is projected to grow at a CAGR of over 15% in the next five years. 

Next Generation Sequencing (NGS) is revolutionising genetic testing by enabling precise, comprehensive analysis of genetic variations, empowering clinicians with actionable insights for personalized patient care. 

The Myeloid Genomics Testing and Precision Assay is designed to offer faster, more precise insights into cancer and myeloid disorders. The Myeloid Genomics Testing covers 79 genes, including those linked to inherited risks, to detect key genetic changes like mutations and fusions. This enables personalised treatment recommendations for conditions like Acute Myeloid Leukemia (AML) and Myeloproliferative Neoplasms (MPN). Reports are reviewed by expert pathologists and include internationally recognized risk assessment tools and therapy suggestions tailored to the patient.

The Genomic Profiling Precision Assay provides comprehensive genomic profiling for cancers like lung, colon, breast, and melanoma by analyzing 50 critical genes. 

Currently, the labs in the genomic testing space often take up to 2 -3 weeks to deliver results for myeloid malignancies, which can delay critical clinical decisions. In contrast, Agilus Diagnostics’ rapid testing approach significantly shortens the diagnostic timeline, reducing hospital visits and enhancing the patient experience.